Inhibition of pathological retinal angiogenesis by the integrin αvβ3 antagonist tetraiodothyroacetic acid (tetrac)

Experimental Eye Research

Volumn 94, Issue 1, 2012, Pages 41-48

  Yoshida, Takeshi ^a   Gong, Junsong ^a   Xu, Zhenhua ^a   Wei, Yanhong ^a   Duh, Elia J ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

Angiogenesis; Erythropoietin; Integrin v 3; Oxygen induced retinopathy; Retinal endothelial cells; VEGF

Indexed keywords

ANGIOGENESIS INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TETRAIODOTHYROACETIC ACID; UNCLASSIFIED DRUG; VITRONECTIN RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; DIABETIC RETINOPATHY; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RETINA; RETINA NEOVASCULARIZATION; RETINOPATHY;

ANGIOGENESIS INHIBITORS; ANIMALS; BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; CELL SURVIVAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENDOTHELIUM, VASCULAR; ERYTHROPOIETIN; HUMANS; INTEGRIN ALPHAVBETA3; INTRAVITREAL INJECTIONS; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; OXYGEN; PHOSPHORYLATION; RETINAL NEOVASCULARIZATION; THYROXINE; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84855847746     PISSN: 00144835     EISSN: 10960007     Source Type: Journal    
DOI: 10.1016/j.exer.2011.11.003     Document Type: Article

References (39)

1. Abràmoff M.D., Magalhães P.J., Ram S.J. Image processing with imageJ. Biophoton. Int. 2004, 11:36-42.
2. Adamis A.P., Altaweel M., Bressler N.M., Cunningham E.T., Davis M.D., Goldbaum M., Gonzales C., Guyer D.R., Barrett K., Patel M. Changes in retinal neovascularization after pegaptanib (Macugen) therapy in diabetic individuals. Ophthalmology 2006, 113:23-28.
3. Adamis A.P., Miller J.W., Bernal M.T., D'Amico D.J., Folkman J., Yeo T.K., Yeo K.T. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am. J. Ophthalmol. 1994, 118:445-450.
4. Aiello L.P. Angiogenic pathways in diabetic retinopathy. N.Engl. J. Med. 2005, 353:839-841.
5. Aiello L.P., Avery R.L., Arrigg P.G., Keyt B.A., Jampel H.D., Shah S.T., Pasquale L.R., Thieme H., Iwamoto M.A., Park J.E., et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N.Engl. J. Med. 1994, 331:1480-1487.
6. Aiello L.P., Pierce E.A., Foley E.D., Takagi H., Chen H., Riddle L., Ferrara N., King G.L., Smith L.E. Suppression of retinal neovascularization invivo by inhibition of vascular endothelial growth factor (VEGF) using soluble VEGF-receptor chimeric proteins. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:10457-10461.
7. Anagnostou A., Lee E.S., Kessimian N., Levinson R., Steiner M. Erythropoietin has a mitogenic and positive chemotactic effect on endothelial cells. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:5978-5982.
8. Avery R.L., Pearlman J., Pieramici D.J., Rabena M.D., Castellarin A.A., Nasir M.A., Giust M.J., Wendel R., Patel A. Intravitreal bevacizumab (Avastin) in the treatment of proliferative diabetic retinopathy. Ophthalmology 2006, 113(1695):e1691-e1695.
9. Bergh J.J., Lin H.Y., Lansing L., Mohamed S.N., Davis F.B., Mousa S., Davis P.J. Integrin alphaVbeta3 contains a cell surface receptor site for thyroid hormone that is linked to activation of mitogen-activated protein kinase and induction of angiogenesis. Endocrinology 2005, 146:2864-2871.
10. Brooks P.C., Montgomery A.M., Rosenfeld M., Reisfeld R.A., Hu T., Klier G., Cheresh D.A. Integrin alpha v beta 3 antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994, 79:1157-1164.
11. Chen J., Connor K.M., Aderman C.M., Willett K.L., Aspegren O.P., Smith L.E. Erythropoietin siRNA suppresses retinal neovascularization in a mouse model of proliferative retinopathy. Invest. Ophthalmol. Vis. Sci. 2008.
12. Connor K.M., Krah N.M., Dennison R.J., Aderman C.M., Chen J., Guerin K.I., Sapieha P., Stahl A., Willett K.L., Smith L.E. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat. Protoc. 2009, 4:1565-1573.
13. Davis F.B., Mousa S.A., O'Connor L., Mohamed S., Lin H.Y., Cao H.J., Davis P.J. Proangiogenic action of thyroid hormone is fibroblast growth factor-dependent and is initiated at the cell surface. Circ. Res. 2004, 94:1500-1506.
14. Duh E.J., Yang H.S., Suzuma I., Miyagi M., Youngman E., Mori K., Katai M., Yan L., Suzuma K., West K., Davarya S., Tong P., Gehlbach P., Pearlman J., Crabb J.W., Aiello L.P., Campochiaro P.A., Zack D.J. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest. Ophthalmol. Vis. Sci. 2002, 43:821-829.
15. Friedlander M., Theesfeld C.L., Sugita M., Fruttiger M., Thomas M.A., Chang S., Cheresh D.A. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc. Natl. Acad. Sci. U.S.A. 1996, 93:9764-9769.
16. Glinskii A.B., Glinsky G.V., Lin H.Y., Tang H.Y., Sun M., Davis F.B., Luidens M.K., Mousa S.A., Hercbergs A.H., Davis P.J. Modification of survival pathway gene expression in human breast cancer cells by tetraiodothyroacetic acid (tetrac). Cell Cycle 2009, 8:3554-3562.
17. Im E., Venkatakrishnan A., Kazlauskas A. Cathepsin B regulates the intrinsic angiogenic threshold of endothelial cells. Mol. Biol. Cell 2005, 16:3488-3500.
18. Jardeleza M.S., Miller J.W. Review of anti-VEGF therapy in proliferative diabetic retinopathy. Semin. Ophthalmol. 2009, 24:87-92.
19. Katsura Y., Okano T., Matsuno K., Osako M., Kure M., Watanabe T., Iwaki Y., Noritake M., Kosano H., Nishigori H., Matsuoka T. Erythropoietin is highly elevated in vitreous fluid of patients with proliferative diabetic retinopathy. Diabetes Care 2005, 28:2252-2254.
20. Luna J., Tobe T., Mousa S.A., Reilly T.M., Campochiaro P.A. Antagonists of integrin alpha v beta 3 inhibit retinal neovascularization in a murine model. Lab. Invest. 1996, 75:563-573.
21. Maiti D., Xu Z., Duh E.J. Vascular endothelial growth factor induces MEF2C and MEF2-dependent activity in endothelial cells. Invest. Ophthalmol. Vis. Sci. 2008, 49:3640-3648.
22. Mousa S.A., Bergh J.J., Dier E., Rebbaa A., O'Connor L.J., Yalcin M., Aljada A., Dyskin E., Davis F.B., Lin H.Y., Davis P.J. Tetraiodothyroacetic acid, a small molecule integrin ligand, blocks angiogenesis induced by vascular endothelial growth factor and basic fibroblast growth factor. Angiogenesis 2008, 11:183-190.
23. Mousa S.A., Davis F.B., Mohamed S., Davis P.J., Feng X. Pro-angiogenesis action of thyroid hormone and analogs in a three-dimensional invitro microvascular endothelial sprouting model. Int. Angiol. 2006, 25:407-413.
24. Ojima T., Takagi H., Suzuma K., Oh H., Suzuma I., Ohashi H., Watanabe D., Suganami E., Murakami T., Kurimoto M., Honda Y., Yoshimura N. EphrinA1 inhibits vascular endothelial growth factor-induced intracellular signaling and suppresses retinal neovascularization and blood-retinal barrier breakdown. Am. J. Pathol. 2006, 168:331-339.
25. Ribatti D., Presta M., Vacca A., Ria R., Giuliani R., Dell'Era P., Nico B., Roncali L., Dammacco F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization invivo. Blood 1999, 93:2627-2636.
26. Robbins S.G., Brem R.B., Wilson D.J., O'Rourke L.M., Robertson J.E., Westra I., Planck S.R., Rosenbaum J.T. Immunolocalization of integrins in proliferative retinal membranes. Invest. Ophthalmol. Vis. Sci. 1994, 35:3475-3485.
27. Smith L.E., Wesolowski E., McLellan A., Kostyk S.K., D'Amato R., Sullivan R., D'Amore P.A. Oxygen-induced retinopathy in the mouse. Invest. Ophthalmol. Vis. Sci. 1994, 35:101-111.
28. Somanath P.R., Ciocea A., Byzova T.V. Integrin and growth factor receptor alliance in angiogenesis. Cell. Biochem. Biophys. 2009, 53:53-64.
29. Somanath P.R., Malinin N.L., Byzova T.V. Cooperation between integrin alphavbeta3 and VEGFR2 in angiogenesis. Angiogenesis 2009, 12:177-185.
30. Stupack D.G., Cheresh D.A. Integrins and angiogenesis. Curr. Top. Dev. Biol. 2004, 64:207-238.
31. Tong Z., Yang Z., Patel S., Chen H., Gibbs D., Yang X., Hau V.S., Kaminoh Y., Harmon J., Pearson E., Buehler J., Chen Y., Yu B., Tinkham N.H., Zabriskie N.A., Zeng J., Luo L., Sun J.K., Prakash M., Hamam R.N., Tonna S., Constantine R., Ronquillo C.C., Sadda S., Avery R.L., Brand J.M., London N., Anduze A.L., King G.L., Bernstein P.S., Watkins S., Jorde L.B., Li D.Y., Aiello L.P., Pollak M.R., Zhang K. Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:6998-7003.
32. Watanabe D., Suzuma K., Matsui S., Kurimoto M., Kiryu J., Kita M., Suzuma I., Ohashi H., Ojima T., Murakami T., Kobayashi T., Masuda S., Nagao M., Yoshimura N., Takagi H. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N.Engl. J. Med. 2005, 353:782-792.
33. Xu Z., Maiti D., Kisiel W., Duh E.J. Tissue factor pathway inhibitor-2 is upregulated by vascular endothelial growth factor and suppresses growth factor-induced proliferation of endothelial cells. Arterioscler. Thromb. Vasc. Biol. 2006, 26:2819-2825.
34. Xu Z., Yu Y., Duh E.J. Vascular endothelial growth factor upregulates expression of ADAMTS1 in endothelial cells through protein kinase C signaling. Invest. Ophthalmol. Vis. Sci. 2006, 47:4059-4066.
35. Yalcin M., Bharali D.J., Dyskin E., Dier E., Lansing L., Mousa S.S., Davis F.B., Davis P.J., Mousa S.A. Tetraiodothyroacetic acid and tetraiodothyroacetic acid nanoparticle effectively inhibit the growth of human follicular thyroid cell carcinoma. Thyroid 2010, 20:281-286.
36. Yalcin M., Bharali D.J., Lansing L., Dyskin E., Mousa S.S., Hercbergs A., Davis F.B., Davis P.J., Mousa S.A. Tetraidothyroacetic acid (tetrac) and tetrac nanoparticles inhibit growth of human renal cell carcinoma xenografts. Anticancer Res. 2009, 29:3825-3831.
37. Yalcin M., Dyskin E., Lansing L., Bharali D.J., Mousa S.S., Bridoux A., Hercbergs A.H., Lin H.Y., Davis F.B., Glinsky G.V., Glinskii A., Ma J., Davis P.J., Mousa S.A. Tetraiodothyroacetic acid (tetrac) and nanoparticulate tetrac arrest growth of medullary carcinoma of the thyroid. J.Clin. Endocrinol. Metab. 2010, 95:1972-1980.
38. Zachary I. VEGF signalling: integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. 2003, 31:1171-1177.
39. Zhande R., Karsan A. Erythropoietin promotes survival of primary human endothelial cells through PI3K-dependent, NF-kappaB-independent upregulation of Bcl-xL. Am. J. Physiol. Heart Circ. Physiol. 2007, 292:H2467-H2474.